Digital Health Round-Up: DTA 2023 Highlights; Pear Assets; Medtronic’s Spin-Off; New Business
Executive Summary
In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb and Hannah Daniel discuss highlights from their DTA Summit coverage in Washington. Reed Miller talked to Frank Chan, the president of Medtronic’s Patient Monitoring, about plans for their patient monitoring as an independent company and Bayer AG’s new business unit focusing on digital health.
You may also be interested in...
Click Therapeutics And Indivior Collaborate On Prescription Digital Therapeutics In Substance Use Disorder
Click Therapeutics and Indivior will develop a digital solution for treating substance use disorders, starting with opioid use disorders. Click already signed partnership deals with Otsuka and Verily and Boehringer Mannheim to co-develop digital therapeutics for patients with schizophrenia and major depressive disorder.
DTA Panel Discusses Future Of Digital Therapeutics, Obstacles To Wider Adoption
A panel discussion between health professionals, industry groups and digital therapeutics innovators at the DTA Summit highlighted opportunities and barriers for the development and adoption of digital therapeutics.
The Afterlife Of Pear Therapeutics: Korean DTx Maker Discusses Vision For Salvaged Migraine Assets
WELT USA was among four companies that competed at auction for Pear assets following the digital therapeutics trailblazer’s Chapter 11 bankruptcy filing in April. WELT also bid on Pear’s reSET assets for treating substance use disorder, but was pleased that they went to Pear’s former CEO Corey McCann – “a good signal to the industry,” says WELT USA head Danny Kim.